GLYCOFLEX® STAGE 2 CHEWABLE TABLETS (120)
Moderate strength joint support chews for adult, maturing and competitive dogs.
If shipping out of the US, please call 802-878-5508.
GlycoFlex® 2 is veterinarian formulated to support your dogs joint health, comfort and mobility. It features 600 mg of Perna canaliculus, 500 mg of MSM, 100 mg of our patented DMG (N,N-Dimethylglycine) and 750 mg of glucosamine HCI. GlycoFlex® 2 also includes glucosamine to support healthy cartilage and MSM, a sulfur compound that is necessary to form connective tissue in joints. GlycoFlex® 2 is formulated to support a lifetime of healthy joints in a tasty chewable tablet!
Directions for Use: Initial: (4 - 6 Weeks)
Up to 30 lbs: 1/2 tablet daily
31 - 60 lbs: 1 tablet daily
61 - 100 lbs: 2 tablets daily
101 lbs and over: 2 1/2 tablets daily
Maintenance: (After initial period)
Up to 30 lbs: 1/2 tablet every other day
31 - 60 lbs: 1/2 tablet daily
61 - 100 lbs: 1 tablet daily
101 lbs and over: 1 1/2 tablets daily
If giving more than 1 tablet, divide between AM and PM.
Active Ingredients Per Tablet (3.1g):
Glucosamine HCl (Shrimp and Crab) 750 mg
Perna canaliculus (GlycOmega brand
Green-Lipped Mussel) 600 mg
Methylsulfonylmethane (MSM) 500 mg
N,N-Dimethylglycine HCl (DMG) 100 mg
Manganese (Mn Amino Acid Chelate) 10 mg
Inactive Ingredients: brewers yeast, dicalcium phosphate, microcrystalline cellulose,
natural imitation chicken flavor, silicon dioxide, stearic acid.
CAUTION:Safe use in pregnant animals or animals intended for breeding has not been proven.
CAUTION:If lameness worsens, discontinue use and contact your veterinarian.
CAUTION:Administer during or after the animal has eaten to reduce incidence of gastrointestinal upset.
Store in a cool, dry place.
For use in dogs only.
WARNING:For animal use only.
WARNING:Keep out of the reach of children and animals. In case of accidental overdose, contact a health professional immediately.
GlycOmega is a Trademark of Aroma New Zealand LTD.
- Moderate strength joint support
- Working and sporting breeds
- Mobility issues
- Healthy recovery